
    
      A study evaluating safety and efficacy of CBM.CD19-targeted chimeric antigen receptor T cells
      (C-CAR011) treatment in subjects with acute lymphoblastic leukemia(ALL) after hematopoietic
      stem cell transplantation（HSCT）. The amount of cells received：1.0-5.0×10^6CAR+T cells/kg
    
  